PFE Dec 2025 60.000 put
| Previous close | 30.17 |
| Open | 30.44 |
| Bid | 31.00 |
| Ask | 31.90 |
| Strike | 60.00 |
| Expiry date | 2025-12-19 |
| Day's range | 30.08 - 30.44 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
Motley FoolLooking for Dividend Growth in the New Year? 3 Magnificent Stocks to Buy Now.
For that reason, as you prepare your portfolio for the next investing year, it's a great idea to add a few dividend stocks to the mix. Which dividend stocks should you select? Plus, the sooner you get in on these players, the sooner you can start collecting dividends.
ZacksPfizer (PFE) Declines More Than Market: Some Information for Investors
In the most recent trading session, Pfizer (PFE) closed at $28.79, indicating a -1.03% shift from the previous trading day.
- Reuters
UPDATE 4-AbbVie to buy drug developer Cerevel for $8.7 billion
AbbVie said on Wednesday it would buy Cerevel Therapeutics, a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its arthritis drug Humira faces a raft of new competition. It marks the second large deal for AbbVie in the past week, coming days after it agreed to buy cancer drug developer ImmunoGen for $10.1 billion in cash, highlighting its appetite to place big bets on promising new medicines. It is paying $45 per share in cash for Cerevel, which is developing drugs for Alzheimer's, Parkinson's, psychosis, epilepsy, and panic disorder.
